PHARMATEK · Hématologie

Calculateur du MIPI continu corrigé de 2008 pour le lymphome à cellules du manteau

Calculer le score brut du MIPI continu original corrigé et l’audit des valeurs saisies à partir d’une évaluation préthérapeutique complète et vérifiée d’un lymphome à cellules du manteau.

Révision clinique en cours

La révision clinique doit être complétée.

Cet outil fait partie de la bibliothèque PharmaTek. Son calcul reste indisponible au public jusqu’à la validation de sa formule, de ses limites et de ses sources.

Explorer les outils accessibles

Sources, population et validation

État: clinical-review-pending
Version de la méthode: Hoster et al. corrected continuous original 2008 Mantle Cell Lymphoma International Prognostic Index (MIPI), engine original-continuous-mipi-2008-erratum-corrected-v1: raw MIPI = 0.03535 × age at first diagnosis in years + 0.6978 when externally recorded ECOG performance status >1 (ECOG 2-4; otherwise 0) + 1.367 × log10(serum total LDH / same issuing report local ULN) + 0.9393 × log10(total peripheral-blood WBC in cells/µL). Both logarithms are base 10. Age is a finite decimal number of years at first diagnosis with the workflow guard age >=18, and ECOG is the externally recorded integer 0, 1, 2, 3, or 4. A verified total peripheral-blood WBC entered in 10^9/L is multiplied by exactly 1000 to cells/µL before log10; the entered 10^9/L numeric is never inserted directly into the corrected WBC logarithm. Serum total LDH and its same-report local ULN are fixed to U/L and must retain exact analyte, reference-limit, report, assay-context, and unit identities. Exact ECOG 0 or 1 contributes 0; ECOG 2, 3, or 4 contributes 0.6978; LDH equal to its ULN gives log10(1) = 0. All four verified values from one complete contemporaneous pretreatment baseline are required. Output is limited to the raw full-precision JavaScript score, four individual terms, normalized ratio and log10 values, and entered-value audit without clamping, rounding, truncation, or a separate display value; no group, cutoff, category, outcome estimate, survival or mortality estimate, probability, individual prognosis, diagnosis, treatment, disposition, monitoring, recommendation, management, or care decision is supplied.
Population: Original source cohort: 455 treatment-naive patients with centrally reviewed mantle cell lymphoma, Ann Arbor stage III/IV, and selection as fit for moderate-intensity chemotherapy, enrolled in GLSG1996, GLSG2000, or European MCL Trial 1 from May 1996 through October 2004. The final multivariable model and source cutpoints used 409 complete cases. This v1 workflow requires an adult at specialist-confirmed first mantle cell lymphoma diagnosis, newly diagnosed and treatment-naive, with age, externally recorded ECOG 0-4, serum total LDH and its same-report local ULN, and total peripheral-blood WBC from one complete contemporaneous pretreatment baseline. Original advanced-stage source applicability or explicit specialist transport acceptance is required, and historical trial-treatment and current-era transport must be explicitly acknowledged.
Limites et exclusions: Use to establish, confirm, exclude, or classify mantle cell lymphoma; pediatric use; relapse or refractory disease; post-treatment reassessment; or use outside the original newly diagnosed, treatment-naive, advanced-stage, moderate-intensity-chemotherapy source context without independent specialist transport acceptance. · Missing, unknown, inferred, imputed, defaulted, carried-forward, incomplete, mixed-timepoint, later, or post-treatment values; an app-inferred ECOG grade; conversion from Karnofsky or another performance scale; age, ECOG, LDH, ULN, or WBC from different assessments; or an unverified timing, source, report, assay context, analyte, specimen, reference limit, or unit identity. · Non-total or non-serum LDH; LDH without the same issuing report's local ULN; a universal absolute LDH threshold; an LDH ratio entered in place of source measurements; LDH and ULN from different reports, assay contexts, or units; unsupported or converted LDH units; non-total or non-peripheral-blood WBC; unsupported WBC units; cells/µL entered into the fixed 10^9/L field; direct use of the entered 10^9/L WBC numeric inside log10 without the exact ×1000 normalization; or rounded, truncated, clamped, or display-formatted arithmetic. · Simplified MIPI; biologic MIPI or MIPI-b; combined MIPI or MIPI-c; Ki-67, genetic, molecular, revised, secondary, or BTKi-MIPI variants; source-defined group cutoffs; any group, risk adjective, survival or mortality estimate, probability, individual prognosis, diagnostic conclusion, treatment, disposition, monitoring, recommendation, management, or care decision.

Origine de l’outil PharmaTek

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source: PharmaTek · MDose
Version importée: 4b66536936ed
État de publication: Révision clinique en cours

POURSUIVRE AVEC MDOSE

Un outil. Un premier lien.

Recevez des nouvelles des outils ou discutez d’une collaboration. L’utilisation de PharmaTek reste accessible sans laisser vos coordonnées.

Médecins et partenaires